JEONJINBIO Co., Ltd.

As of June 30, 2026, JEONJINBIO Co., Ltd. carries a market capitalization of 15.94B, placing it among publicly traded companies globally. Its enterprise value stands at 9.66B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, JEONJINBIO Co., Ltd. has 9.06M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.16, and the price-to-book ratio stands at 0.94.

As of June 30, 2026, JEONJINBIO Co., Ltd. trades at an EV/EBITDA multiple of 68.77 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.70 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 9.66B versus a market cap of 15.94B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, JEONJINBIO Co., Ltd. maintains a current ratio of 7.96, meaning it holds 8.0x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, JEONJINBIO Co., Ltd. posted a negative return on equity (ROE) of -1.79, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -1.66, reflecting losses generated across the asset base. The company generates approximately 435.39M in revenue per employee across its workforce of 31.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 6.97 indicates how many times JEONJINBIO Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 23, 2026, JEONJINBIO Co., Ltd.'s stock has declined approximately 26.56% over the past 52 weeks. The 50-day moving average sits at 2,040.72, while the 200-day moving average is 2,104.86.

Over the twelve months ended June 30, 2026, JEONJINBIO Co., Ltd. generated 13.71B in revenue and converted that into -307.03M in net income, yielding earnings per share of -33.84. EBITDA reached 140.45M, while operating income came in at -413.26M.

These figures are as of June 30, 2026. Total book value stands at 17.02B, with working capital of 8.52B providing operational flexibility.

JEONJINBIO Co., Ltd. produced 1.03B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -32.91M in capital expenditures, free cash flow totaled 994.82M - equivalent to 109.66 per share.

Over the twelve months ended June 30, 2026, JEONJINBIO Co., Ltd. posted a gross margin of 26.04, reflecting its pricing power and cost economics. The operating margin of -3.01 and net profit margin of -2.24 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 6.23, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt.

JEONJINBIO Co., Ltd.'s most recent stock split took place on October 19, 2020 with a 193:210 split ratio.

As of June 30, 2026, JEONJINBIO Co., Ltd. has an Altman Z-Score of 5.47, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.